European urology oncology最新文献

筛选
英文 中文
Recent and Future Developments in the Use of Poly (ADP-ribose) Polymerase Inhibitors for Prostate Cancer.
IF 8.3 1区 医学
European urology oncology Pub Date : 2024-12-04 DOI: 10.1016/j.euo.2024.11.011
Francesca Zacchi, Wassim Abida, Emmanuel S Antonarakis, Alan H Bryce, Elena Castro, Heather H Cheng, Shahneen Shandhu, Joaquin Mateo
{"title":"Recent and Future Developments in the Use of Poly (ADP-ribose) Polymerase Inhibitors for Prostate Cancer.","authors":"Francesca Zacchi, Wassim Abida, Emmanuel S Antonarakis, Alan H Bryce, Elena Castro, Heather H Cheng, Shahneen Shandhu, Joaquin Mateo","doi":"10.1016/j.euo.2024.11.011","DOIUrl":"https://doi.org/10.1016/j.euo.2024.11.011","url":null,"abstract":"<p><strong>Background and objective: </strong>Advanced prostate cancer (PCa) is enriched for alterations in DNA damage repair genes; poly (ADP-ribose) polymerase (PARP) inhibitors (PARPi) are a class of drugs that have demonstrated effectiveness in PCa, particularly in tumors with alterations in BRCA1/2 and other homologous recombination repair (HRR) genes, acting through a synthetic lethal mechanism. To prevent or delay drug resistance, and to expand the patient population that can benefit from this class of drug, combination treatment strategies have been developed in preclinical and clinical studies.</p><p><strong>Methods: </strong>This review examines the latest developments in clinical trials testing PARPi for advanced PCa and their emerging role in earlier disease settings. Furthermore, it discusses the critical role of careful patient selection and identification of additional biomarkers to enhance treatment efficacy.</p><p><strong>Key findings and limitations: </strong>Two PARPi (olaparib and rucaparib) have been approved as monotherapy in metastatic castration-resistant PCa, thereby establishing the first biomarker-guided drug indications in PCa. Several combinations of PARPi with androgen receptor pathway inhibitors have now also been approved. Anemia and fatigue are the main adverse events associated with this drug class in clinical trials; gastrointestinal toxicities are common but usually manageble.</p><p><strong>Conclusions and clinical implications: </strong>PARPi are active against PCa with HRR mutations, especially in those with germline or somatic BRCA1/2 mutations.  There is still a need to further optimize patient stratification strategies, particularly for combination approaches. Future research should focus on refining predictive biomarkers, improving treatment delivery strategies, and exploring the potential benefits of PARPi in earlier stages of the disease.</p><p><strong>Patient summary: </strong>Here, we summarize the results from clinical trials testing different poly (ADP-ribose) polymerase inhibitors (PARPi), a novel targeted drug class, in prostate cancer. Overall, the data from these trials confirm the efficacy of this drug class in those metastatic prostate cancers that show specific gene alterations, such as mutations in the BRCA1/2 genes. Several studies combining PARPi with other standard drugs for prostate cancer suggest that there may be efficacy in larger patient populations, but some of these data still need validation in longer follow-up analyses.</p>","PeriodicalId":12256,"journal":{"name":"European urology oncology","volume":" ","pages":""},"PeriodicalIF":8.3,"publicationDate":"2024-12-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142785024","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Circulating Tumor DNA: A New Research Frontier in Urological Oncology from Localized to Metastatic Disease.
IF 8.3 1区 医学
European urology oncology Pub Date : 2024-12-02 DOI: 10.1016/j.euo.2024.11.008
Marianna Garofoli, Brigida Anna Maiorano, Giuseppina Bruno, Guido Giordano, Ugo Giovanni Falagario, Andrea Necchi, Giuseppe Carrieri, Matteo Landriscina, Vincenza Conteduca
{"title":"Circulating Tumor DNA: A New Research Frontier in Urological Oncology from Localized to Metastatic Disease.","authors":"Marianna Garofoli, Brigida Anna Maiorano, Giuseppina Bruno, Guido Giordano, Ugo Giovanni Falagario, Andrea Necchi, Giuseppe Carrieri, Matteo Landriscina, Vincenza Conteduca","doi":"10.1016/j.euo.2024.11.008","DOIUrl":"https://doi.org/10.1016/j.euo.2024.11.008","url":null,"abstract":"<p><strong>Background and objective: </strong>Circulating tumor DNA (ctDNA) testing provides valuable prognostic and predictive information for guiding therapeutic choices and monitoring disease progression and drug resistance for urological tumors. Our review focuses on emerging opportunities for ctDNA analysis in urological tumors and the development of potential circulating biomarkers within a multidisciplinary framework to improve personalized treatment.</p><p><strong>Methods: </strong>A nonsystematic literature review was conducted in the PubMed and MEDLINE databases. Prospective and retrospective peer-reviewed studies, review articles, and research abstracts on the use of ctDNA for urological tumors were included.</p><p><strong>Key findings and limitations: </strong>Several studies have demonstrated that ctDNA analysis is a promising tool that can help clinicians in the diagnosis and clinical management of urological tumors. In prostate and urothelial cancers, the ctDNA fraction increases proportionally from localized to metastatic disease, indicating a higher tumor burden and more aggressive behavior. Thus, ctDNA seems to be a useful tool for improving prognostic risk stratification and treatment selection. Data on the use of liquid biopsy in renal cell carcinoma are still limited, and assessment of prognostic and predictive biomarkers is a critical unmet need.</p><p><strong>Conclusions and clinical implications: </strong>ctDNA analysis promises to revolutionize the management of urological tumors in different disease settings. Integration of ctDNA testing in routine clinical practice will require a multidisciplinary approach that involve patients, clinicians, and molecular biologists.</p><p><strong>Patient summary: </strong>We reviewed how testing for tumor DNA in blood (circulating tumor DNA, ctDNA) is used in urological cancers. A great deal of evidence supports the usefulness of this noninvasive test. However, further research via a multidisciplinary approach is needed before ctDNA testing becomes part of routine patient care.</p>","PeriodicalId":12256,"journal":{"name":"European urology oncology","volume":" ","pages":""},"PeriodicalIF":8.3,"publicationDate":"2024-12-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142767634","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Small Testicular Masses: An Individualized Approach Is Warranted.
IF 8.3 1区 医学
European urology oncology Pub Date : 2024-12-02 DOI: 10.1016/j.euo.2024.11.012
Axel Heidenreich
{"title":"Small Testicular Masses: An Individualized Approach Is Warranted.","authors":"Axel Heidenreich","doi":"10.1016/j.euo.2024.11.012","DOIUrl":"https://doi.org/10.1016/j.euo.2024.11.012","url":null,"abstract":"","PeriodicalId":12256,"journal":{"name":"European urology oncology","volume":" ","pages":""},"PeriodicalIF":8.3,"publicationDate":"2024-12-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142767648","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Role of Mitomycin C in Intermediate-risk Non-muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis. 丝裂霉素 C 在中危非肌层浸润性膀胱癌中的作用:系统回顾与元分析》。
IF 8.3 1区 医学
European urology oncology Pub Date : 2024-12-01 Epub Date: 2024-06-19 DOI: 10.1016/j.euo.2024.06.005
Pietro Scilipoti, Aleksander Ślusarczyk, Mario de Angelis, Francesco Soria, Benjamin Pradere, Wojciech Krajewski, David D'Andrea, Andrea Mari, Francesco Del Giudice, Renate Pichler, José Daniel Subiela, Luca Afferi, Simone Albisinni, Laura Mertens, Ekaterina Laukhtina, Keiichiro Mori, Piotr Radziszewski, Shahrokh F Shariat, Andrea Necchi, Evanguelos Xylinas, Paolo Gontero, Morgan Rouprêt, Francesco Montorsi, Alberto Briganti, Marco Moschini
{"title":"The Role of Mitomycin C in Intermediate-risk Non-muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis.","authors":"Pietro Scilipoti, Aleksander Ślusarczyk, Mario de Angelis, Francesco Soria, Benjamin Pradere, Wojciech Krajewski, David D'Andrea, Andrea Mari, Francesco Del Giudice, Renate Pichler, José Daniel Subiela, Luca Afferi, Simone Albisinni, Laura Mertens, Ekaterina Laukhtina, Keiichiro Mori, Piotr Radziszewski, Shahrokh F Shariat, Andrea Necchi, Evanguelos Xylinas, Paolo Gontero, Morgan Rouprêt, Francesco Montorsi, Alberto Briganti, Marco Moschini","doi":"10.1016/j.euo.2024.06.005","DOIUrl":"10.1016/j.euo.2024.06.005","url":null,"abstract":"<p><strong>Background and objective: </strong>Intravesical mitomycin C (MMC) instillations are recommended to prevent recurrence of intermediate-risk non-muscle-invasive bladder cancer (IR-NMIBC); however, the optimal regimen and dose are uncertain. Our aim was to assess the effectiveness of adjuvant MMC and compare different MMC regimens in preventing recurrence.</p><p><strong>Methods: </strong>We performed a comprehensive search in PubMed, Scopus, and Web of Science in November 2023 for studies investigating recurrence-free survival (RFS) among patients with IR-NMIBC who received adjuvant MMC. Prospective trials with different MMC regimens or other intravesical drugs as comparators were considered eligible.</p><p><strong>Key findings and limitations: </strong>Overall, 14 studies were eligible for systematic review and 11 for meta-analysis of RFS. Estimates of 1-yr, 2-yr, and 5-yr RFS rates were 84% (95% confidence interval [CI] 79-89%), 75% (95% CI 68-82%), and 51% (95% CI 40-63%) for patients treated with MMC induction plus maintenance, and 88% (95% CI 83-94%), 78% (95% CI 67-89%), and 66% (95% CI 57-75%) for patients treated with bacillus Calmette-Guérin (BCG) maintenance, respectively. Estimates of 2-yr RFS rates for MMC maintenance regimens were 76% (95% CI 69-84%) for 40 mg MMC (2 studies) and 66% (95% CI 60-72%) for 30 mg MMC (4 studies). Among the studies included, BCG maintenance provided comparable 2-yr RFS to 40 mg MMC with maintenance (78% vs 76%). RFS did not differ by MMC maintenance duration (>1 yr vs 1 yr vs <1 yr).</p><p><strong>Conclusions and clinical implications: </strong>MMC induction and maintenance regimens seem to provide short-term RFS rates equivalent to those for BCG maintenance in IR-NMIBC. For adjuvant induction and maintenance, 40 mg of MMC appears to be more effective in preventing recurrence than 30 mg. We did not observe an RFS benefit for longer maintenance regimens.</p><p><strong>Patient summary: </strong>For patients with intermediate-risk non-muscle-invasive bladder cancer, bladder treatments with a solution of a drug called mitomycin C (MMC) seem to be as effective as BCG (bacillus Calmette-Guérin) in preventing recurrence after tumor removal. Further trials are needed for stronger evidence on the best MMC dose and treatment time.</p>","PeriodicalId":12256,"journal":{"name":"European urology oncology","volume":" ","pages":"1293-1302"},"PeriodicalIF":8.3,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141431697","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clinical Validation of the Intermediate-risk Non-muscle-invasive Bladder Cancer Scoring System and Substratification Model Proposed by the International Bladder Cancer Group: A Multicenter Young Academic Urologists Urothelial Working Group Collaboration. 国际膀胱癌小组提出的中危非肌层浸润性膀胱癌评分系统和分层模型的临床验证:国际膀胱癌小组提出的中危非肌层浸润性膀胱癌评分系统和基质化模型:多中心青年泌尿科医师泌尿系统工作组合作。
IF 8.3 1区 医学
European urology oncology Pub Date : 2024-12-01 Epub Date: 2024-06-20 DOI: 10.1016/j.euo.2024.06.004
Francesco Soria, Matteo Rosazza, Simone Livoti, Marco Moschini, Mario De Angelis, Francesco Del Giudice, Renate Pichler, Rodolfo Hurle, Stefano Mancon, Diego M Carrion, Wojciech Krajewski, Laura S Mertens, David D'Andrea, Andrea Mari, Fabrizio Di Maida, Daniele Dutto, Fulvia Colucci, Giulia Casale, Giorgia Fertitta, Ekaterina Laukhtina, Simone Albisinni, Benjamin Pradere, Jeremy Y C Teoh, Shahrokh F Shariat, Alberto Briganti, Ashish M Kamat, Paolo Gontero
{"title":"Clinical Validation of the Intermediate-risk Non-muscle-invasive Bladder Cancer Scoring System and Substratification Model Proposed by the International Bladder Cancer Group: A Multicenter Young Academic Urologists Urothelial Working Group Collaboration.","authors":"Francesco Soria, Matteo Rosazza, Simone Livoti, Marco Moschini, Mario De Angelis, Francesco Del Giudice, Renate Pichler, Rodolfo Hurle, Stefano Mancon, Diego M Carrion, Wojciech Krajewski, Laura S Mertens, David D'Andrea, Andrea Mari, Fabrizio Di Maida, Daniele Dutto, Fulvia Colucci, Giulia Casale, Giorgia Fertitta, Ekaterina Laukhtina, Simone Albisinni, Benjamin Pradere, Jeremy Y C Teoh, Shahrokh F Shariat, Alberto Briganti, Ashish M Kamat, Paolo Gontero","doi":"10.1016/j.euo.2024.06.004","DOIUrl":"10.1016/j.euo.2024.06.004","url":null,"abstract":"<p><strong>Background and objective: </strong>Intermediate-risk (IR) non-muscle-invasive bladder cancer (NMIBC) encompasses a broad spectrum of disease, with heterogeneous outcomes in terms of disease recurrence and progression. The International Bladder Cancer Group (IBCG) recently proposed an updated scoring model for IR substratification that is based on five key risk factors. Our aim was to provide a clinical validation of the IBCG scoring system and substratification model for IR NMIBC.</p><p><strong>Methods: </strong>This was an international multicenter retrospective study. Patients diagnosed with IR NMIBC between 2012 and 2022 and treated with transurethral resection of the bladder and adjuvant intravesical chemotherapy were included. According to the presence or absence of risk factors, patients with IR NMIBC were further categorized in IR-low (no risk factors), IR-intermediate (1-2 risk factors), and IR-high (≥3 risk factors) groups. The 1-yr and 3-yr rates for recurrence-free survival (RFS) and progression-free survival (PFS) were evaluated for each subgroup. Cox regression analyses were used to compare oncological outcomes between the groups.</p><p><strong>Key findings and limitations: </strong>Of the 677 patients with IR NMIBC included in the study, 231 (34%), 364 (54%), and 82 (12%) were categorized in the IR-low, IR-intermediate, and IR-high groups, respectively. There were significant differences in RFS and PFS rates between these groups.</p><p><strong>Conclusions and clinical implications: </strong>We provide the first clinical validation of the IBCG scoring system and model for substratification of IR NMIBC.</p><p><strong>Patient summary: </strong>Our study demonstrates that patients with intermediate-risk non-muscle-invasive bladder cancer can be correctly classified into three distinct subgroups according to their risk of both disease recurrence and progression. Our results support use of this scoring system in clinical practice.</p>","PeriodicalId":12256,"journal":{"name":"European urology oncology","volume":" ","pages":"1497-1503"},"PeriodicalIF":8.3,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141436795","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Role of Baseline Prostate-specific Antigen Value Prior to Age 60 in Predicting Lethal Prostate Cancer: Analysis of a Contemporary North American Cohort. 60 岁前前列腺特异抗原基线值在预测致命前列腺癌中的作用:对当代北美队列的分析。
IF 8.3 1区 医学
European urology oncology Pub Date : 2024-12-01 Epub Date: 2024-07-10 DOI: 10.1016/j.euo.2024.06.014
Marco Finati, Matthew Davis, Alex Stephens, Giuseppe Chiarelli, Giuseppe Ottone Cirulli, Chase Morrison, Rafe Affas, Akshay Sood, Nicolò Buffi, Giovanni Lughezzani, Alberto Briganti, Francesco Montorsi, Giuseppe Carrieri, Craig Rogers, Andrew Julian Vickers, Firas Abdollah
{"title":"The Role of Baseline Prostate-specific Antigen Value Prior to Age 60 in Predicting Lethal Prostate Cancer: Analysis of a Contemporary North American Cohort.","authors":"Marco Finati, Matthew Davis, Alex Stephens, Giuseppe Chiarelli, Giuseppe Ottone Cirulli, Chase Morrison, Rafe Affas, Akshay Sood, Nicolò Buffi, Giovanni Lughezzani, Alberto Briganti, Francesco Montorsi, Giuseppe Carrieri, Craig Rogers, Andrew Julian Vickers, Firas Abdollah","doi":"10.1016/j.euo.2024.06.014","DOIUrl":"10.1016/j.euo.2024.06.014","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Background and objective: &lt;/strong&gt;Studies evaluating the role of baseline midlife prostate-specific antigen (PSA) as a predictor of development and progression of prostate cancer relied predominately on cohorts from the pre-PSA screening introduction era. The aim of our study was to examine the role of baseline PSA prior to the age of 60 yr as a predictor of developing lethal prostate cancer using a contemporary North American cohort.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;Our cohort included all men aged 40-59 yr who received their first PSA through our health system between the years 1995 and 2019. Patients were divided into four categories based on age: 40-44, 45-49, 50-54, and 55-59 yr. Baseline PSA was the predictor of interest. Lethal disease was defined as death from prostate cancer or development of metastatic disease either at diagnosis or during follow-up. Cancer-specific mortality and overall mortality were obtained by linking our database to the Michigan Vital Records registry. Competing-risk regression was used to evaluate the association between PSA and lethal prostate cancer.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Key findings and limitations: &lt;/strong&gt;A total of 129067 men met the inclusion criteria during the study period. The median follow-up for patients free from cancer was 7.4 yr. For men aged 40-44, 45-49, 50-54, and 55-59 yr, the estimated rates of lethal prostate cancer at 20 yr were 0.02%, 0.14%, 0.33%, and 0.51% in men with PSA &lt;median, and 0.79%, 0.16%, 2.5%, and 5.4% in men with PSA ≥90th percentile, respectively. For the same age category, the estimated rates of any prostate cancer at 20 yr were, respectively, 1.6%, 2.9%, 3.9%, and 5.8% in men with PSA &lt;median, and 25%, 28%, 38%, and 39% in men with PSA ≥90th percentile. On a multivariable analysis, men with PSA ≥90th percentile had a hazard ratio of 7.48 (95% confidence interval [CI]: 6.20-9.03) for lethal disease, when compared with those with PSA &lt;median. On the multivariable analysis, men with PSA ≥90th percentile had a hazard ratio of 20.47-fold (95% CI: 18.58-22.55) for prostate cancer incidence, when compared with those with PSA &lt;median at first. Limitations included shorter median follow-up than prior literature.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusions and clinical implications: &lt;/strong&gt;Baseline PSA is a very strong predictor of the subsequent risk of developing lethal prostate cancer in a large contemporary diverse North American cohort, which was exposed to opportunistic PSA screening. The association was far larger than that found for polygenic risk scores, confirming that baseline PSA prior to the age of 60 yr is the most effective tool for adjusting subsequent screening. Compared with studies of unscreened cohorts, there was a smaller difference in discrimination between incident and lethal disease, reflecting the influence of screening.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Patient summary: &lt;/strong&gt;In this study, we found that a single baseline prostate-specific antigen (PSA) value is strongly predictive of t","PeriodicalId":12256,"journal":{"name":"European urology oncology","volume":" ","pages":"1535-1542"},"PeriodicalIF":8.3,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141590043","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Re: Laura Elst, Manon T.A. Vreeburg, Hielke Martijn de Vries, et al. Corporal Skip Metastases in Penile Squamous Cell Carcinoma: An Unknown and Distinct Pattern of Spread with Poor Prognosis. Eur Urol Oncol. In press. https://doi.org/10.1016/j.euo.2023.09.005. Re:Laura Elst, Manon T.A. Vreeburg, Hielke Martijn de Vries, et al. 阴茎鳞状细胞癌的下体跳部转移:预后不良的未知和独特扩散模式。欧洲泌尿肿瘤杂志》。https://doi.org/10.1016/j.euo.2023.09.005.
IF 8.3 1区 医学
European urology oncology Pub Date : 2024-12-01 Epub Date: 2024-03-11 DOI: 10.1016/j.euo.2024.01.020
Marco Bandini, Andrea Salonia, Francesco Montorsi
{"title":"Re: Laura Elst, Manon T.A. Vreeburg, Hielke Martijn de Vries, et al. Corporal Skip Metastases in Penile Squamous Cell Carcinoma: An Unknown and Distinct Pattern of Spread with Poor Prognosis. Eur Urol Oncol. In press. https://doi.org/10.1016/j.euo.2023.09.005.","authors":"Marco Bandini, Andrea Salonia, Francesco Montorsi","doi":"10.1016/j.euo.2024.01.020","DOIUrl":"10.1016/j.euo.2024.01.020","url":null,"abstract":"","PeriodicalId":12256,"journal":{"name":"European urology oncology","volume":" ","pages":"1548"},"PeriodicalIF":8.3,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140109785","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Room for improvement when approaching RCC in the solitary kidney: surgery is not the only choice. 治疗单肾 RCC 的改进空间:手术并非唯一选择。
IF 8.3 1区 医学
European urology oncology Pub Date : 2024-12-01 Epub Date: 2024-09-28 DOI: 10.1016/j.euo.2024.09.009
Rohann J M Correa, Alexander V Louie, Shankar Siva
{"title":"Room for improvement when approaching RCC in the solitary kidney: surgery is not the only choice.","authors":"Rohann J M Correa, Alexander V Louie, Shankar Siva","doi":"10.1016/j.euo.2024.09.009","DOIUrl":"10.1016/j.euo.2024.09.009","url":null,"abstract":"","PeriodicalId":12256,"journal":{"name":"European urology oncology","volume":" ","pages":"1164-1165"},"PeriodicalIF":8.3,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142344438","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Unlocking the Potential of Adequate Bacillus Calmette-Guérin Immunotherapy in Very-high-risk Non-muscle-invasive Bladder Carcinoma: A Multicenter Analysis of Oncological Outcomes and Risk Dynamics. 挖掘充分的卡介苗-Guérin免疫疗法在极高风险非肌层浸润性膀胱癌中的潜力:肿瘤学结果和风险动态的多中心分析。
IF 8.3 1区 医学
European urology oncology Pub Date : 2024-12-01 Epub Date: 2024-02-13 DOI: 10.1016/j.euo.2024.01.017
José Daniel Subiela, Wojciech Krajewski, Daniel A González-Padilla, Jan Laszkiewicz, Javier Taborda, Júlia Aumatell, Miguel Sanchez Encinas, Giuseppe Basile, Marco Moschini, Jorge Caño-Velasco, Enrique Lopez Perez, Pedro Del Olmo Durán, Andrea Gallioli, Andrzej Tukiendorf, David D'Andrea, Jeremy Yuen-Chun Teoh, Alejandra Serna Céspedes, Renate Pichler, Luca Afferi, Francesco Del Giudice, Juan Gomez Rivas, Simone Albisinni, Francesco Soria, Guillaume Ploussard, Laura S Mertens, Paweł Rajwa, Ekaterina Laukhtina, Benjamin Pradere, Karl Tully, Félix Guerrero-Ramos, Óscar Rodríguez-Faba, Mario Alvarez-Maestro, Jose Luis Dominguez-Escrig, Tomasz Szydełko, Victoria Gomez Dos Santos, Miguel Ángel Jiménez Cidre, Francisco Javier Burgos Revilla
{"title":"Unlocking the Potential of Adequate Bacillus Calmette-Guérin Immunotherapy in Very-high-risk Non-muscle-invasive Bladder Carcinoma: A Multicenter Analysis of Oncological Outcomes and Risk Dynamics.","authors":"José Daniel Subiela, Wojciech Krajewski, Daniel A González-Padilla, Jan Laszkiewicz, Javier Taborda, Júlia Aumatell, Miguel Sanchez Encinas, Giuseppe Basile, Marco Moschini, Jorge Caño-Velasco, Enrique Lopez Perez, Pedro Del Olmo Durán, Andrea Gallioli, Andrzej Tukiendorf, David D'Andrea, Jeremy Yuen-Chun Teoh, Alejandra Serna Céspedes, Renate Pichler, Luca Afferi, Francesco Del Giudice, Juan Gomez Rivas, Simone Albisinni, Francesco Soria, Guillaume Ploussard, Laura S Mertens, Paweł Rajwa, Ekaterina Laukhtina, Benjamin Pradere, Karl Tully, Félix Guerrero-Ramos, Óscar Rodríguez-Faba, Mario Alvarez-Maestro, Jose Luis Dominguez-Escrig, Tomasz Szydełko, Victoria Gomez Dos Santos, Miguel Ángel Jiménez Cidre, Francisco Javier Burgos Revilla","doi":"10.1016/j.euo.2024.01.017","DOIUrl":"10.1016/j.euo.2024.01.017","url":null,"abstract":"<p><strong>Background: </strong>The European Association of Urology (EAU) recommends discussing upfront radical cystectomy for all patients with very high risk (VHR) non-muscle-invasive bladder carcinoma (NMIBC), but the role of bacillus Calmette-Guérin (BCG) treatment remains controversial.</p><p><strong>Objective: </strong>To analyze oncological outcomes in VHR NMIBC patients (EAU risk groups) treated with adequate BCG.</p><p><strong>Design, setting, and participants: </strong>A multi-institutional retrospective study involving patients with VHR NMIBC who received adequate BCG therapy from 2007 to 2020 was conducted.</p><p><strong>Outcome measurements and statistical analysis: </strong>A survival analysis estimated recurrence-free survival (RFS), progression-free survival (PFS), and the cumulative incidence of cancer-specific mortality (CSM) after accounting for other causes of mortality as competing risk events and of the overall mortality (OM). Conditional survival probabilities for 0-4 yr without events were computed. Cox regression assessed the predictors of oncological outcomes.</p><p><strong>Results and limitation: </strong>A total of 640 patients, with a median 47 (32-67) mo follow-up for event-free individuals, were analyzed. High-grade RFS and PFS at 5 yr were 53% (49-57%) and 78% (74-82%), respectively. The cumulative incidence of CSM and OM at 5 yr was 13% (10-16%) and 16% (13-19%), respectively. Conditional RFS, PFS, overall survival, and cancer-specific survival at 4 yr were 91%, 96%, 87%, and 94%, respectively. Cox regression identified tumor grade (hazard ratio [HR]: 1.54; 1.1-2) and size (HR: 1.3; 1.1-1.7) as RFS predictors. Tumor multiplicity predicted RFS (HR: 1.6; 1.3-2), PFS (HR: 2; 1.2-3.3), and CSM (HR: 2; 1.2-3.2), while age predicted OM (HR: 1.48; 1.1-2).</p><p><strong>Conclusions: </strong>Patients with VHR NMIBC who receive adequate BCG therapy have a more favorable prognosis than predicted by EAU risk groups, especially among those with a sustained response, in whom continuing maintenance therapy emerges as a viable alternative to radical cystectomy.</p><p><strong>Patient summary: </strong>Our research shows that a sustained response to bacillus Calmette-Guérin in patients can lead to favorable outcomes, serving as a viable alternative to cystectomy for select cases.</p>","PeriodicalId":12256,"journal":{"name":"European urology oncology","volume":" ","pages":"1367-1375"},"PeriodicalIF":8.3,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139734852","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Adjuvant Atezolizumab in Patients with Sarcomatoid Renal Cell Carcinoma: A Prespecified Subgroup Analysis of IMmotion010. 肉瘤型肾细胞癌患者的阿特珠单抗辅助治疗:IMMOTION010 的预设亚组分析。
IF 8.3 1区 医学
European urology oncology Pub Date : 2024-12-01 Epub Date: 2024-07-01 DOI: 10.1016/j.euo.2024.06.006
Jose Antonio Karam, Robert Uzzo, Axel Bex, William Leung, Connie Tat, Alan Nicholas, Alexander Andreev-Drakhlin, Mahrukh Huseni, Sumanta Kumar Pal, Viraj A Master
{"title":"Adjuvant Atezolizumab in Patients with Sarcomatoid Renal Cell Carcinoma: A Prespecified Subgroup Analysis of IMmotion010.","authors":"Jose Antonio Karam, Robert Uzzo, Axel Bex, William Leung, Connie Tat, Alan Nicholas, Alexander Andreev-Drakhlin, Mahrukh Huseni, Sumanta Kumar Pal, Viraj A Master","doi":"10.1016/j.euo.2024.06.006","DOIUrl":"10.1016/j.euo.2024.06.006","url":null,"abstract":"<p><p>Patients with sarcomatoid renal cell carcinoma (sRCC) have a poor prognosis. In the randomised, double-blind phase 3 IMmotion010 trial (NCT03024996), adjuvant atezolizumab did not demonstrate a disease-free survival (DFS) benefit versus placebo in the overall population of patients with locoregional renal cell carcinoma with an increased risk of recurrence following surgery. This prespecified subgroup analysis of efficacy and safety was completed in 104 patients with sRCC. Baseline characteristics were similar between treatment arms. At a median follow-up of 45 mo, the median DFS was not evaluable (NE; 95% confidence interval [CI], 12 mo-NE) in the atezolizumab arm (n = 37) and 23 mo (95% CI, 11-NE) in the placebo arm (n = 66; hazard ratio 0.77 [95% CI, 0.44-1.4]). In the sRCC subgroup, grade 3/4 treatment-related adverse events (TRAEs) occurred in one patient (2.7%) in the atezolizumab arm and two patients (3.0%) in the placebo arm. By comparison, 54 of 353 patients (15%) and 16 of 317 patients (5.0%) with non-sarcomatoid histology reported grade 3/4 TRAEs in the respective arms. In conclusion, the difference in DFS was not statistically significant between adjuvant atezolizumab and placebo in patients with sRCC. The safety profile was similar between patients with sRCC and non-sRCC. PATIENT SUMMARY: Patients with a specific type of locoregional kidney cancer (tumours with sarcomatoid features) were treated with atezolizumab or placebo after surgery. Slightly more patients treated with atezolizumab lived longer without the disease getting worse than those treated with placebo, although this finding was not statistically significant. The side effects were similar to those seen in patients with other types of kidney cancer treated with atezolizumab in the same study (IMmotion010). In patients with sarcomatoid kidney cancer, atezolizumab was tolerable and may be more effective than placebo, but this requires further study.</p>","PeriodicalId":12256,"journal":{"name":"European urology oncology","volume":" ","pages":"1175-1178"},"PeriodicalIF":8.3,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141491506","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信